JAMA July 17, 2002

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial

Writing Group for the Women's Health Initiative Investigators (Jacques E. Rossouw, Garnet L. Anderson, Ross L. Prentice, et al.)

Source: View publication →

Bottom Line

The WHI trial demonstrated that the long-term use of combined estrogen plus progestin in healthy postmenopausal women increases the risk of coronary heart disease, stroke, pulmonary embolism, and breast cancer, which outweighs the benefits of reduced fractures and colorectal cancer.

Key Findings

1. The trial was stopped early after a mean follow-up of 5.2 years because the test statistic for invasive breast cancer exceeded the pre-established stopping boundary and the global index supported overall risks exceeding benefits [1.1].

2. Combined hormone therapy increased the risk of the primary outcome, coronary heart disease, by 29% (HR 1.29; 95% CI, 1.02-1.63).

3. Estrogen plus progestin significantly increased the risk of invasive breast cancer (HR 1.26; 95% CI, 1.00-1.59), stroke (HR 1.41; 95% CI, 1.07-1.85), and pulmonary embolism (HR 2.13; 95% CI, 1.39-3.25).

4. Treatment provided significant benefits in reducing the risk of colorectal cancer (HR 0.63; 95% CI, 0.43-0.92) and hip fractures (HR 0.66; 95% CI, 0.45-0.98).

5. The global index, summarizing the overall balance of risks and benefits, showed a 15% increased risk of adverse events in the estrogen plus progestin group (HR 1.15; 95% CI, 1.03-1.28).

6. Absolute excess risks per 10,000 person-years attributable to the combined therapy were 7 more CHD events, 8 more strokes, 8 more pulmonary embolisms, and 8 more invasive breast cancers, offset by 6 fewer colorectal cancers and 5 fewer hip fractures.

Study Design

Design

RCT

Double-Blind

Sample

16,608

Patients

Duration

5.2 yr

Median

Setting

Multicenter, US

Population Healthy postmenopausal women aged 50 to 79 years with an intact uterus.

Intervention Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d) in a single daily tablet.

Comparator Matching placebo tablet.

Outcome Coronary heart disease (nonfatal myocardial infarction and CHD death), with invasive breast cancer designated as the primary adverse outcome.

Study Limitations

• High rates of nonadherence and study medication discontinuation over time (42% in the estrogen plus progestin group and 38% in the placebo group) [1.5].

• The study population was relatively older (mean age 63.2 years) and many women were years past the onset of menopause, limiting generalizability to younger women newly transitioning into menopause who typically initiate therapy for severe vasomotor symptoms.

• The trial evaluated only one specific oral hormone regimen (0.625 mg/d of conjugated equine estrogens plus 2.5 mg/d of medroxyprogesterone acetate); these risks may not uniformly apply to lower systemic doses, transdermal administration routes, or different progestin formulations.

Clinical Significance

The WHI trial profoundly transformed the landscape of women's health by refuting the long-held belief that hormone replacement therapy is broadly cardioprotective. It established that combined continuous estrogen plus progestin should not be prescribed for the primary prevention of chronic diseases. Consequently, modern guidelines restrict hormone therapy primarily to the management of moderate-to-severe menopausal symptoms, utilizing the lowest effective dose for the shortest duration necessary.

Historical Context

Prior to the WHI, vast amounts of observational data (most notably early reports from the Nurses' Health Study) strongly suggested that postmenopausal hormone replacement therapy reduced the risk of coronary heart disease by as much as 40-50%. Consequently, HRT was routinely prescribed globally for both chronic disease prevention and its presumed anti-aging benefits. The WHI was specifically designed to definitively confirm these cardioprotective benefits in a randomized, double-blind fashion. Its unexpected early termination in 2002 due to net harm sent shockwaves through the medical community, leading to a precipitous global decline in HRT prescriptions and serving as a landmark cautionary tale about the limitations of observational epidemiology in medicine.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the physiological mechanisms by which oral combined estrogen and progestin therapy increases the risk of venous thromboembolism (VTE) and pulmonary embolism (PE) in postmenopausal women?

Key Response

Oral estrogen undergoes first-pass metabolism in the liver, stimulating the synthesis of procoagulant factors (such as factor VII, X, and prothrombin) and decreasing the production of anticoagulants (such as antithrombin and protein S), which shifts the hemostatic balance toward a prothrombotic state.

Resident

A 52-year-old postmenopausal woman with an intact uterus presents with severe, quality-of-life-limiting vasomotor symptoms. Given the WHI findings of increased risks, how do you counsel her regarding the initiation, duration, and formulation of hormone replacement therapy (HRT)?

Key Response

While the WHI demonstrated risks of long-term HRT for primary prevention in older women, current consensus supports short-term systemic HRT (estrogen plus progestin for endometrial protection) for severe vasomotor symptoms in women under 60 or within 10 years of menopause onset, as absolute risks are very low in this group and benefits for symptom relief are high.

Fellow

How did the age distribution and time since menopause of the WHI cohort impact the generalizability of its cardiovascular outcomes, and what is the 'timing hypothesis' that emerged to contextualize these findings?

Key Response

The average age of WHI participants was 63. The 'timing hypothesis' suggests that initiating HRT early in menopause may be cardioprotective by slowing early atherogenesis via healthy endothelium, whereas late initiation (as in many WHI subjects) may destabilize existing atherosclerotic plaques via pro-inflammatory and pro-thrombotic effects, explaining the increased CHD risk in the older WHI cohort.

Attending

The publication of the WHI trial led to a drastic, population-wide decline in HRT prescriptions. Looking back, what crucial lessons does this offer regarding the translation of RCT data to individual patient care and avoiding therapeutic pendulum swings?

Key Response

The WHI tested HRT specifically for chronic disease prevention in generally older postmenopausal women, but its results were inappropriately generalized to deny short-term HRT for symptom management in newly menopausal women. It teaches the imperative of matching the study population and intent (prevention vs. symptom control) to the clinical scenario before universally applying relative risk findings.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The WHI trial utilized a 'global index' statistic to summarize the overall balance of risks and benefits. What are the methodological strengths and limitations of using such a composite index in a trial with highly heterogeneous endpoints like fractures, breast cancer, and CHD?

Key Response

A global index provides a single summary measure to curb alpha-inflation from multiple testing and provides a net clinical effect. However, its major limitation is that it inherently assumes equal clinical weight for vastly different endpoints (e.g., equating a hip fracture with a fatal myocardial infarction), which oversimplifies competing risks and ignores differential impacts on quality of life.

Journal Editor

Given the exceedingly high rates of study medication discontinuation (42% in the active group) and 'drop-ins' (placebo subjects initiating outside HRT), how does this crossover affect the interpretation of the intention-to-treat (ITT) analysis for the WHI's primary safety endpoints?

Key Response

High crossover and discontinuation rates heavily bias ITT results toward the null (a conservative estimate). A critical reviewer would flag that because the WHI still detected statistically significant increases in CHD and breast cancer despite this massive dilution effect, the true biological risk of the combined HRT regimen is likely even higher than the reported hazard ratios suggest.

Guideline Committee

Based on the WHI findings and subsequent long-term follow-up data, how do current ACOG and USPSTF guidelines classify the level of evidence for using HRT for the primary prevention of cardiovascular disease, and what is the explicit recommendation?

Key Response

Based directly on the robust WHI trial data (Level A evidence), current ACOG, NAMS, and USPSTF guidelines strongly recommend against the routine use of combined estrogen and progestin for the primary prevention of cardiovascular disease or other chronic conditions, representing a definitive, evidence-based reversal of pre-2002 clinical consensus.

Clinical Landscape

Noteworthy Related Trials

1998

Heart and Estrogen/progestin Replacement Study (HERS)

n = 2,763 · JAMA

Tested

Conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) daily

Population

Postmenopausal women with established coronary heart disease

Comparator

Placebo

Endpoint

Nonfatal myocardial infarction or CHD death

Key result: Estrogen plus progestin therapy did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and increased the rate of thromboembolic events.

2004

Women's Health Initiative Estrogen-Alone Trial

n = 10,739 · JAMA

Tested

Conjugated equine estrogens (0.625 mg/d) alone

Population

Postmenopausal women with prior hysterectomy

Comparator

Placebo

Endpoint

Coronary heart disease and breast cancer

Key result: Estrogen alone did not increase or decrease CHD risk, significantly increased the risk of stroke and deep vein thrombosis, and did not increase breast cancer risk.

2016

Early versus Late Intervention Trial with Estradiol (ELITE)

n = 643 · NEJM

Tested

Oral 17-beta estradiol (1 mg/d) plus vaginal progesterone gel

Population

Healthy postmenopausal women stratified by time since menopause

Comparator

Placebo

Endpoint

Rate of change in carotid-artery intima-media thickness (CIMT)

Key result: Estradiol therapy reduced the progression of subclinical atherosclerosis when initiated early after menopause but not when initiated late.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis